Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
View Older Stories View More Recent Stories
-
Apple design chief Jony Ive, Steve Jobs' confidant, to leave and start own firm
-
Maxim Group Downgrades Atossa Genetics (ATOS) to Hold
-
Theralase Files Prospectus for Offering of Units
-
Maxim Group Starts Envision Solar International (EVSI) at Buy
-
Maxim Group Starts Titan Pharmaceuticals (TTNP) at Buy
-
AZTherapies to Present at Maxim Group’s Conference on Alzheimer’s Disease
-
MedTech Outlook Names Co-Diagnostics Inc as Top 10 In-Vitro Diagnostic Provider for 2019
-
MedTech Outlook Names Co-Diagnostics Inc as Top 10 In-Vitro Diagnostic Provider for 2019
-
DelMar Pharmaceuticals Announces Extension Of Rights Offering To July 12, 2019
-
Artelo Biosciences Announces Closing of $8.0 Million Public Offering and Partial Exercise and Closing of Over-Allotment Option
-
Maxim Group Starts Cassava Sciences (SAVA) at Buy
-
Neurotrope CEO to Present at the Maxim Group Key Opinion Leader Discussion on Alzheimer's Disease on June 26th, 2019
-
Aristotle (ARTL) Prices 1.3M Share Unit Offering at $6.15/Unit; Announces 1-for-8 Reverse Share Split
-
Artelo Biosciences Announces Pricing of $8.0 Million Public Offering and Uplisting to Nasdaq
-
Del Taco Restaurants (TACO) PT Raised to $15 at Maxim Group
-
Maxim Group Starts HyreCar Inc. (HYRE) at Buy
-
Gladstone Land (LAND) Prices 2M Share Common Offering at $11.73/Sh
-
Gladstone Land Corporation Announces Pricing of Common Stock Offering
-
Gladstone Land Corporation Announces Pricing of Common Stock Offering
-
SELLAS Life Sciences Announces Closing of $15 Million Public Offering
-
Cassava Sciences to Present at Maxim Group’s Conference on Alzheimer’s Disease
-
Cassava Sciences to Present at Maxim Group’s Conference on Alzheimer’s Disease
-
Maxim Group Upgrades bluebird bio (BLUE) to Buy
-
Soliton (SOLY) Reports $9.45 Million Private Placement of Common Stock, Warrants
-
Soliton Announces $9.45 Million Private Placement
-
Pre-Open Movers 06/14: (ARQL) (FVRR) (UA) Higher; (MCRB) (AVGO) (APRN) (more...)
-
SELLAS Life Sciences (SLS) Prices $15 Million Public Offering of Common Stock, Warrants
-
SELLAS Life Sciences Announces Pricing of $15 Million Public Offering
-
UPDATE: Maxim Group Upgrades Red Robin Gourmet Burgers (RRGB) to Buy
-
UPDATE: Maxim Group Starts Achieve Life Sciences (ACHV) at Buy
-
UPDATE: Maxim Group Starts Hemispherx (HEB) at Buy
-
Galaxy Next Generation Engages Maxim Group for Investment Banking Services
-
Fastbase Inc. Retains Maxim Group LLC to Provide Financial Advisory and Investment Banking Services
-
Fastbase Inc. Retains Maxim Group LLC to Provide Financial Advisory and Investment Banking Services
-
Maxim Group Downgrades Denny's Corporation (DENN) to Hold
-
Maxim Group Starts ContraFect Corp. (CFRX) at Buy
-
Delmar Pharmaceuticals Updates The Terms Of Previously Announced Rights Offering
-
Dawson James Securities Appoints Jason Kolbert to Director of Research
-
Maxim Group Starts Reebonz (RBZ) at Buy
-
Maxim Group Starts UMH Properties (UMH) at Buy
-
MICT, Inc. (MICT) says group to invest between $9M and $16.25M in company
-
Strategic investment of up to $16.25M in MICT, with at least $9M funded at the closings
-
DelMar Pharmaceuticals Announces Closing of Financing
-
NV5 Holdings (NVEE) PT Raised to $95 at Maxim Group
-
Redefy Corporation* Announces Up to $6 Million Private Securities Offering
-
Redefy Corporation* Announces Up to $6 Million Private Securities Offering
-
Cracker Barrel (CBRL) PT Lowered to $185 at Maxim Group
-
Maxim Group Upgrades Texas Roadhouse (TXRH) to Buy
-
Aegion Corporation to Attend Upcoming Investor Conferences
-
Delmar Pharma (DMPI) Announces 1.17M Share Registered Direct Offering at $3.10/Sh

